Autoimmune Diseases最新文献

{"title":"Evidence for Molecular Mimicry between SARS-CoV-2 and Human Antigens: Implications for Autoimmunity in COVID-19.","authors":"Andrea Arévalo-Cortés, Daniel Rodriguez-Pinto, Leonardo Aguilar-Ayala","doi":"10.1155/2024/8359683","DOIUrl":"10.1155/2024/8359683","url":null,"abstract":"<p><p>As for other viral diseases, the mechanisms behind the apparent relationship between COVID-19 and autoimmunity are yet to be clearly defined. Molecular mimicry, the existence of sequence and/or conformational homology between viral and human antigens, could be an important contributing factor. Here, we review the accumulated evidence supporting the occurrence of mimicry between SARS-CoV-2 and human proteins. Both bioinformatic approaches and antibody cross-reactions have yielded a significant magnitude of mimicry events, far more common than expected to happen by chance. The clinical implication of this phenomenon is ample since many of the identified antigens may participate in COVID-19 pathophysiology or are targets of autoimmune diseases. Thus, autoimmunity related to COVID-19 may be partially explained by molecular mimicry and further research designed specifically to address this possibility is needed.</p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2024 ","pages":"8359683"},"PeriodicalIF":1.7,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics of Systemic Lupus Erythematosus in Caucasians and Latin American Hispanics: Data from a Single Tertiary Center.","authors":"Luca Marri, Chiara Vassallo, Pasquale Esposito, Luca Bottaro, Raffaele De Palma, Simone Negrini","doi":"10.1155/2024/5593302","DOIUrl":"10.1155/2024/5593302","url":null,"abstract":"<p><strong>Background: </strong>Different studies report that systemic lupus erythematosus (SLE) tends to have a more aggressive course in Hispanic patients. In this study, we analysed epidemiologic, clinical, and laboratory characteristics in a cohort of Hispanic and Caucasian lupus patients in the context of Italian health service, which provides free access to care to all citizens, thus mitigating the impact of socioeconomic factors that negatively influence the course of the disease in ethnic minorities.</p><p><strong>Methods: </strong>This single-center retrospective study was conducted at the San Martino Hospital \"Lupus Clinic\" in Genoa, Italy. Patients ≥18 years with a confirmed diagnosis of SLE and definite ethnicity (Hispanic or Caucasian) were recruited.</p><p><strong>Results: </strong>A total of 126 patients (90 Caucasians and 36 Hispanics) were enrolled. We compared epidemiologic characteristics, clinical features, autoantibodies profile, and treatment options without evidencing any statistically significant difference between the two groups, except for disease duration, which was higher in the Caucasian group (20.4 years versus 14.2 years in the Hispanic group, <i>P</i>=0.002) and SLICC damage index, which was greater in Caucasian patients (2.11 versus 1.88 in Hispanics, <i>P</i>=0.037), but this difference was no longer significant after correction for disease duration (<i>P</i>=0.096).</p><p><strong>Conclusions: </strong>In our cohort, Hispanic ethnicity is not associated with worse disease features and outcomes. Therefore, we speculated that socioeconomic factors, in particular, free access to healthcare, might be more relevant in influencing the course of the disease than genetic background.</p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2024 ","pages":"5593302"},"PeriodicalIF":1.7,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma/Serum Oxidant Parameters in Systemic Lupus Erythematosus Patients: A Systematic Review and Meta-Analysis.","authors":"Napoleon Bellua Sam, Stephen Tabiri, Ebenezer Amofa","doi":"10.1155/2024/9948612","DOIUrl":"10.1155/2024/9948612","url":null,"abstract":"<p><p>Most published results have revealed variations in the association of serum/plasma levels of malondialdehyde (MDA), apolipoprotein B (ApoB), and oxidized low-density lipoprotein (OxLDL) and systemic lupus erythematosus (SLE). This study was performed to establish MDA, ApoB, and OxLDL levels in systemic lupus erythematosus (SLE) patients. Electronic databases were searched for the included articles up to 27th February 2023. The meta-analysis included 48 articles with 2358 SLE patients and 2126 healthy controls considered for MDA, ApoB, and OxLDL levels. There were significantly higher MDA, ApoB, and OxLDL levels in SLE patients than those in the control groups. Subgroup analysis indicated that European/American SLE patients and patients of both ages <36 and ≥36 exhibited higher MDA, ApoB, and OxLDL levels. Arab and Asian SLE patients had higher ApoB and MDA/OxLDL levels. African SLE patients recorded higher OxLDL levels than the control groups. SLE patients with a body mass index (BMI) of ≥23 and a disease duration of <10 recorded significantly higher MDA, ApoB, and OxLDL levels. Patients with systemic lupus erythematosus disease activity index (SLEDAI) ≥8 of SLE had higher MDA and ApoB levels, whereas SLE patients with SLEDAI <8 showed significantly higher ApoB levels. Patients with BMI <23 of SLE had higher MDA and OxLDL levels. This study established significantly higher MDA, ApoB, and OxLDL levels in SLE patients, suggesting a possible role of MDA, ApoB, and OxLDL in the disease.</p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2024 ","pages":"9948612"},"PeriodicalIF":1.7,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141894584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Symptoms and Severity of COVID-19 in Patients with Immune-Mediated Inflammatory Diseases: Experience of a University Medical Center.","authors":"Tobias Schlosser, Marco Krasselt, Louis Elsing, Martin Hecker, Babett Holler, Albrecht Hoffmeister","doi":"10.1155/2024/6627035","DOIUrl":"https://doi.org/10.1155/2024/6627035","url":null,"abstract":"<p><strong>Background: </strong>The pandemic situation of the novel coronavirus (severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) and its associated disease (coronavirus disease 2019 (COVID-19)) represents a challenging condition with a plethora of aspects. The course of COVID-19 in patients with immune-mediated inflammatory diseases (IMID) such as inflammatory bowel disease (IBD) and rheumatic diseases (RD) is not well known. Our study is one step toward closing this gap by collecting data on vaccination rates, infection-free survival, and individual symptom severity.</p><p><strong>Methods: </strong>We conducted a prospective questionnaire-based study between April 2022 and October 2022 at our university hospital. Outward patients over the age of 18 years were screened for participation and reported about their infection/infection-free survival since the start of the pandemic.</p><p><strong>Results: </strong>Finally, 156 patients were included in the study, 117 (75.0%) of which had inflammatory bowel disease and 39 (25.0%) patients with rheumatic disease. Altogether, 143 (91.7%) persons had received at least one vaccination against SARS-CoV-2. A total of 153 patients provided information regarding their COVID-19 history: 81 patients (52.0%) self-reported about their SARS-CoV-2 infection. In general, courses of infection were mild: only two patients (2.5% of patients with reported COVID-19) were hospitalized due to COVID-19 with one (1.2%) of the two needing intensive care. Asymptomatic COVID-19 had been described by 7 persons (8.6% of patients with reported COVID-19). Acute COVID-19 was accompanied by fatigue/tiredness in 58 persons (71.6% of patients with history of COVID-19) as the most frequent symptom. Other complaints were common cold (55 patients = 67.9%), cough (51 patients = 63.0%), headache (44 patients = 54.3%), and fever (35 patients = 43.2%). Stratified by vaccination status (unvaccinated vs. at least once vaccinated), the time to infection differed significantly (logrank test: <i>p</i> = 0.04, Chi² 4.1). At least once vaccinated people had a median COVID-19-free survival of 28.5 months (confidence interval (CI): 23.6 months-not reached). Without any vaccination, the estimated time to infection was 25.1 months (CI: 23.6 months-not reached).</p><p><strong>Conclusion: </strong>Our IMID patients have a high rate of vaccination against SARS-CoV-2. Data show a significantly longer infection-free survival in vaccinated IMID patients as compared to unvaccinated patients. Discrimination between symptoms of COVID-19 and a concomitant inflammatory disease is difficult as complaints might be overlapping. This trial is registered with DRKS00028880.</p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2024 ","pages":"6627035"},"PeriodicalIF":4.0,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comprehensive Review on the Role of Interleukin-40 as a Biomarker for Diagnosing Inflammatory Diseases.","authors":"Feryal Dabbagh-Gorjani","doi":"10.1155/2024/3968767","DOIUrl":"10.1155/2024/3968767","url":null,"abstract":"<p><p>Interleukins are a group of proteins that have a wide range of complex functions and are believed to be involved in several diseases and conditions. In particular, interleukin-40 (IL-40) is a recently identified cytokine associated with B cells that was first introduced by Catalan et al. in 2017. This cytokine has several roles in the body, including functioning in the formation of B cells in the bone marrow, IgA production, and expression in the intestinal microbiome. Moreover, IL-40 appears to be involved in numerous autoimmune and inflammatory conditions, such as rheumatoid arthritis, systemic lupus erythematosus, primary Sjogren's syndrome, ankylosing spondylitis, type 2 diabetes, Graves' disease, and hepatic cell carcinoma. Our understanding of this molecule is quite restricted due to its novelty. However, because of its inflammatory characteristics, there is a high probability that it contributes to a variety of inflammatory disease complications. The aim of the present review is to highlight all available data on the importance of assessing IL-40 levels in human diseases up to now, which could be used as a diagnostic biomarker for the onset or progression of numerous inflammatory diseases.</p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2024 ","pages":"3968767"},"PeriodicalIF":4.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Increasing Level of DKK-1 as a New Bone Formation Factor in Patients with Early Spondyloarthritis.","authors":"Yuliasih Yuliasih,&nbsp;Aghnia Permatasari,&nbsp;Lita Diah Rahmawati,&nbsp;Mohammad Imam Wahyudi,&nbsp;Nabilatun Nisa'","doi":"10.1155/2023/5543234","DOIUrl":"https://doi.org/10.1155/2023/5543234","url":null,"abstract":"<p><p>The role of dickkopf-related protein 1 (DKK-1) in radiographic development may become a robust marker for early spondyloarthritis (SpA) diagnosis. This study aimed at determining the serum DKK-1 profile in patients with SpA and investigating its relationship with SpA progression. Supported by analyzing the BMD data which aims to affirm the potential of DKK-1 as a biomarker for early diagnosis of SpA, this research may become the early study to produce a robust tool to diminish the fatal impacts in SpA. This cross-sectional study included patients with SpA using ASAS 2010 criteria from Dr. Soetomo General Hospital, Indonesia. Collected data included patients' general characteristics, disease duration, disease activity using ASDAS-CRP and ASDAS-ESR, serum DKK-1 levels, and BMD. The patients were classified as early SpA if the disease duration was ≤5 years and established SpA if the disease duration was >5 years, while the low BMD was indicated by <i>Z</i> score ≤ -2.00. The correlation was tested using the Spearman or Pearson test. The differences in patients' characteristics among early and established SpA and also between low and normal BMD were tested using the unpaired <i>T</i>-test or the Mann-Whitney test. The serum DKK-1 levels in early SpA (7365 ± 2067 pg/dL) were significantly higher than those in established SpA (5360 ± 1054 pg/dL). Serum DKK-1 levels were also associated with disease duration (<i>r</i> = -0.370, <i>p</i> = 0.040) and BMD at the total hip (<i>r</i> = 0.467, <i>p</i> = 0.028). The differences in all patients' clinical parameters were not found between patients with low BMD at any site and patients with normal BMD unless in the BMI (<i>p</i> = 0.019). Our findings found DKK-1 as a potential diagnostic marker for early SpA. Early diagnosis may lead to rapid treatment to delay disease progression and prevent future impairment.</p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2023 ","pages":"5543234"},"PeriodicalIF":4.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9620856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management and Outcomes of ANCA-Associated Vasculitis at a Tertiary Healthcare Facility.","authors":"Nabeehah Moollan,&nbsp;Adeel Rafi Ahmed,&nbsp;Mark Denton","doi":"10.1155/2022/4808806","DOIUrl":"https://doi.org/10.1155/2022/4808806","url":null,"abstract":"<p><strong>Results: </strong>Thirty-six patients were included in the final study. Cyclophosphamide was used in 24 patients (66.7%) and, comparatively, rituximab in 7 patients (19.4%) for induction. Seven patients (19.4%) had a documented relapse, and six patients (85.7%) had rituximab as induction therapy for relapse. The majority of patients were on azathioprine (61.1%, 57.1% relapse population) as maintenance therapy. Progression to ESRD occurred in 11 (30.6%), death in 4 (11.1%), established CKD in 15 (41.7%), and preservation of renal function in 6 (16.7%) patients by the end of the follow-up period.</p><p><strong>Conclusions: </strong>While cyclophosphamide remains the choice of induction immunosuppression therapy, we favour rituximab as an induction agent in the relapse of AAV. Despite aggressive immunosuppression therapy, the incidence of ESRD and death remains high in these patients.</p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2022 ","pages":"4808806"},"PeriodicalIF":4.0,"publicationDate":"2022-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39939489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Will 14-3-3<i>η</i> Be a New Diagnostic and Prognostic Biomarker in Rheumatoid Arthritis? A Prospective Study of Its Utility in Early Diagnosis and Response to Treatment.","authors":"Doaa Shawky Alashkar,&nbsp;Radwa Mostafa Elkhouly,&nbsp;Amira Yousef Abd Elnaby,&nbsp;Doaa Waseem Nada","doi":"10.1155/2022/1497748","DOIUrl":"https://doi.org/10.1155/2022/1497748","url":null,"abstract":"<p><strong>Results: </strong>Serum14-3-3<i>η</i> levels were significantly higher in all RA patients than in controls (<i>P</i> < 0.001), its sensitivity was 86.7% and 88.3% in early and established RA patients with a significant difference with RF and ACCP at early disease, and the specificity was 96.7%. There was a significant reduction of 14-3-3<i>η</i> levels 6 months after treatment in the first group (<i>p</i>=0.004), and there was a significant positive correlation between serum 14-3-3<i>η</i> levels and parameters of disease activity and severity.</p><p><strong>Conclusion: </strong>14-3-3<i>η</i> could be a novel, potent, and efficacious diagnostic, and prognostic marker for RA with high sensitivity, that may become a new therapeutic target for RA.</p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2022 ","pages":"1497748"},"PeriodicalIF":4.0,"publicationDate":"2022-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39819859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective Effect of Hyperbaric Oxygen Treatment on Axon Degeneration after Acute Motor Axonal Neuropathy.","authors":"Ni Komang Sri Dewi Untari,&nbsp;Kurnia Kusumastuti,&nbsp;Guritno Suryokusumo,&nbsp;I Ketut Sudiana","doi":"10.1155/2021/6627779","DOIUrl":"10.1155/2021/6627779","url":null,"abstract":"<p><strong>Objectives: </strong>Acute motor axonal neuropathy (AMAN) is a disease that leads to acute flaccid paralysis and may result from the binding of antibody and antigen to the spinal cord. The objective of this study is to evaluate the protective effect of hyperbaric oxygen treatment (HBOT) on axon degeneration of the spinal cord and sciatic nerve of the AMAN model rabbit. Axonal degeneration was assessed by evaluating glutathione (GSH) activity, interleukin-1<i>β</i> (IL-1<i>β</i>) expression, and clinical and histopathological features.</p><p><strong>Methods: </strong>Twenty-one New Zealand rabbits were divided into three groups. The treatment group was exposed to 100% oxygen at 2.4 ATA 90 minutes for 10 days at a decompression rate of 2.9 pounds per square inch/minute. GSH level was evaluated using an enzyme-linked immune-sorbent assay. An expression of IL-1<i>β</i> in the spinal cord was determined by immunohistochemistry. Clinical appearances were done by motor scale and body weight. Histological features observed neuronal swelling and inflammatory infiltration in the sagittal lumbar region and the undulation of the longitudinal sciatic nerve.</p><p><strong>Results: </strong>Rabbits exposed to HBO had high GSH activity levels (<i>p</i> < 0.05) but unexpectedly had high IL1<i>β</i> expression (<i>p</i> > 0.05). In addition, the HBO-exposed rabbits had a better degree of undulation, the size of neuronal swelling was smaller, the number of macrophages was higher, and motor function was better than the AMAN model rabbits (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>These findings indicate that HBO therapy can decrease axon degeneration by triggering GSH activity, increasing IL-1<i>β</i> level, and restoring tissues and motor status. In conclusion, HBO has a protective effect on axon degeneration of the spinal cord and sciatic nerve of the AMAN model rabbit.</p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2021 ","pages":"6627779"},"PeriodicalIF":4.0,"publicationDate":"2021-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39633371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fungal Infections among Psoriatic Patients: Etiologic Agents, Comorbidities, and Vulnerable Population.","authors":"Mostafa Chadeganipour,&nbsp;Shahla Shadzi,&nbsp;Rasoul Mohammadi","doi":"10.1155/2021/1174748","DOIUrl":"https://doi.org/10.1155/2021/1174748","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic inflammatory disorder of the skin and joint, affecting nearly 2-3% of the general population. It is assumed that imbalance between the types of natural microflora can accelerate the onset of the disease. Some fungi can play the role of superantigens and prolong chronic inflammation in the skin of psoriatic patients. The aim of the present investigation was to identify fungal species isolated from patients with psoriasis.</p><p><strong>Methods: </strong>From March 2016 to May 2019, 289 patients with prior diagnosis of psoriasis were included in this survey. Direct microscopy with potassium hydroxide (KOH 10%), culture, urea hydrolysis, hair perforation test, and growth on rice grains were used to identify clinical isolates, phenotypically. For molecular identification of <i>Candida</i> species and <i>Malassezia</i> species, PCR-RFLP and PCR-sequencing were used, respectively.</p><p><strong>Results: </strong>Forty-six out of 289 psoriatic patients had fungal infections (15.9%). Dermatophytes (54.3%), <i>Candida</i> spp. (19.5%), <i>Malassezia</i> spp. (15.2%), <i>Aspergillus</i> spp. (6.5%), and <i>Fusarium</i> spp. (4.3%) were the causative agents of fungal infections. Among <i>Malassezia</i> and <i>Candida</i> species, <i>M. restricta</i> (10.8%) and <i>C. glabrata</i> (8.7%) were the most prevalent species, respectively.</p><p><strong>Conclusion: </strong>Our findings suggested that fungal pathogens, particularly dermatophytes, may play an important role in the pathogenicity of psoriasis. Also, due to the high rate of yeast colonization in the clinical samples of psoriatic patients, concomitant use of anti-inflammatory drugs and antifungals may represent an effective therapeutic approach for better management of chronic lesions among these patients. Mycological tests should be applied to indicate the incidence of fungal diseases in psoriatic patients.</p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2021 ","pages":"1174748"},"PeriodicalIF":4.0,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39452625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}